Cat. No.: HY-B1449

Uridine

(Synonyms: β-Uridine)

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

Uridine (β-Uridine) is a nucleoside compound composed of uracil and a ribose ring, which are connected by a β-N1-glycosidic bond.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 58-96-8
Formula: C₉H₁₂N₂O₆
Molecular Weight:244.20

Storage:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Uridine Chemical Structure

CAS No.: 58-96-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Uridine (β-Uridine) is a nucleoside compound composed of uracil and a ribose ring, which are connected by a β-N1-glycosidic bond^[1].

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	>200 μM Compound: araU	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
H9	EC₅₀	10 μg/mL Compound: uridine	Antiviral activity against HIV1 3B infected in human H9 cells after 4 days by p24 antigen ELISA assay Antiviral activity against HIV1 3B infected in human H9 cells after 4 days by p24 antigen ELISA assay	[PMID: 7775984]
L1210	IC₅₀	>200 μM Compound: araU	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
MOLT-4	IC₅₀	>200 μM Compound: araU	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
RAW264.7	IC₅₀	>10 μM Compound: 21	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 28499733]

In Vitro

Uridine (6-24 mM, 7 days) inhibits the proliferation of leukemia cell HL-60, arrests the cell cycle at G2/M phase, and induces the differentiation of HL-60 into mature cells with characteristics of monocytes and granulocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

HL-60
Concentration:

6-24 mM
Incubation Time:

7 days
Result:

Inhibited the cell proliferation.

In Vivo

Uridine (10-20 mg/kg, oral, 6 weeks) alleviates CCl₄ (HY-Y0298)-induced liver fibrosis, inhibits the expression of pro-inflammatory cytokines and the activation of the NF-κB signaling pathway in mouse liver fibrosis models^[2].
Uridine (30 mg/kg, iv, single dose) exhibits anti-ischemic, antixoxidant and anti-arrhythmic effcts in rats models, exhibits protective efficacy against acute myocardial ischemia and ischemia/reperfusion injury^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse liver fibrosis models^[2]
Dosage:

10-20 mg/kg
Administration:

oral, 6 weeks
Result:

Reduced levels of ALP, ALT and AST in serum, decreased the collagen deposition.

Animal Model:

Rats acute myocardial ischemia (AMI) and ischemia/reperfusion (I/R) models^[3]
Dosage:

30 mg/kg
Administration:

iv, single dose
Result:

Inhibited ischemia-induced lipid peroxidation, reduced the ischemic area, duration of ischemia-induced arrhythmias, the occurrence of premature ventricular beats (PVB) and ventricular tachycardia (VT).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 58-96-8
Appearance Solid
Molecular Weight 244.20
Formula C₉H₁₂N₂O₆
Color White to off-white
SMILES

O[C@H]1[C@@H](O)[C@H](N2C(NC(C=C2)=O)=O)O[C@@H]1CO
Synonyms

β-Uridine
Structure Classification
- Others
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All Bio/Physico-chemical AssayWBCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

Imeta

2026 Feb 24.
Bioact Mater

cGAMP-targeting injectable hydrogel system promotes periodontal restoration by alleviating cGAS-STING pathway activation. [Abstract]

2025 Feb 13:48:55-70. PMID: 40303968
Nat Commun

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [Abstract]

2026 Feb 25;17(1):3142. PMID: 41735312
Cell Death Differ

TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53. [Abstract]

2024 Feb;31(2):239-253. PMID: 38182899
J Adv Res

Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes. [Abstract]

2025 May 10:S2090-1232(25)00309-1. PMID: 40354935

Uridine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 May 10:S2090-1232(25)00309-1. [Abstract]

Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine (10-100 μM) supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay.
Biomed Pharmacother

Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. [Abstract]

2019 Oct:118:109305. PMID: 31545264
Biomed Pharmacother

Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo. [Abstract]

2019 Aug:116:108982. PMID: 31146110

Uridine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Aug:116:108982. [Abstract]

The viral VP1 protein and β-actin were detected by western blot. β-actin was used as an internal control. 25, 50, 200, 200 μM uridine (48 h) were added to FMDV infected IBRS-2 cells, when treated with 75 μmol/L brequinar for 48 h.
Oncogene

The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation. [Abstract]

2025 May;44(16):1078-1092. PMID: 39865175
Cell Prolif

Intercellular mitochondrial transfer alleviates pyroptosis in dental pulp damage. [Abstract]

2023 Sep;56(9):e13442. PMID: 37086012
Int J Mol Sci

Uridine Alleviates Sepsis-Induced Acute Lung Injury by Inhibiting Ferroptosis of Macrophage. [Abstract]

2023 Mar 7;24(6):5093. PMID: 36982166

Uridine purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 7;24(6):5093. [Abstract]

Uridine obviously weakens the expression of ACSL4, which is markedly raised in LPS group in murine lung tissues.
Aquaculture

2025 Feb 15.
ACS Chem Biol

Li-BrU-seq: A Low-Input and Simplified Metabolic Labeling Method for Nascent RNA Sequencing. [Abstract]

2026 Mar 20;21(3):601-612. PMID: 41773915
J Virol

African swine fever virus hijacks host pyrimidine metabolism to promote viral replication. [Abstract]

2025 Nov 25;99(11):e0098525. PMID: 41171159

Uridine purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Nov 25;99(11):e0098525. [Abstract]

Exogenous uridine (50 μM) supplementation restores ASFV-P30 protein levels suppressed by brequinar. For all experiments, PAMs were infected with ASFV at MOI = 1, and cell lysates were collected at 24 hpi for Western blotting.
J Pharm Biomed Anal

A novel UHPLC-MS/MS approach for simultaneous quantification of pyrimidine metabolites in human biofluids. [Abstract]

2025 Jun 17:265:117026. PMID: 40544701
Biochem Biophys Res Commun

Targeting DHODH promoter G-quadruplex to induce ferroptosis in melanoma cells. [Abstract]

2025 Dec 9:795:153117. PMID: 41380445
bioRxiv

2025 Nov 20.
Cell Investig

2025 Sep 30.

Uridine purchased from MedChemExpress. Usage Cited in: Cell Investig. 2025 Sep 30.

Western blot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin, ZEB1, Slug, and Zo-1) in H1299 cells treated with uridine (ERI, 0.25-1 mM) for 48 h.

Uridine purchased from MedChemExpress. Usage Cited in: Cell Investig. 2025 Sep 30.

Uridine (0.25-1 mM; 48 h) promotes LUAD cell migration. Wound healing assay was used to detect the migration ability of A549 cells treated with uridine at different concentration for 48 h.Scale bars: 100 μm.
bioRxiv

2025 Aug 22.
Res Sq

2025 May 12.

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (409.50 mM)

DMSO : 50 mg/mL (204.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0950 mL

20.4750 mL

40.9500 mL

5 mM

0.8190 mL

4.0950 mL

8.1900 mL

10 mM

0.4095 mL

2.0475 mL

4.0950 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (10.24 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 40 mg/mL (163.80 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sokoloski JA, et al., Effects of uridine on the growth and differentiation of HL-60 leukemia cells. Leuk Res. 1991;15(11):1051-8. [Content Brief]

[2]. Zheng WV, et al., Uridine alleviates carbon tetrachloride-induced liver fibrosis by regulating the activity of liver-related cells. J Cell Mol Med. 2022 Feb;26(3):840-854. [Content Brief]

[3]. Krylova IB, et al., Uridine treatment prevents myocardial injury in rat models of acute ischemia and ischemia/reperfusion by activating the mitochondrial ATP-dependent potassium channel. Sci Rep. 2021 Aug 20;11(1):16999. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.0950 mL	20.4750 mL	40.9500 mL	102.3751 mL
	5 mM	0.8190 mL	4.0950 mL	8.1900 mL	20.4750 mL
	10 mM	0.4095 mL	2.0475 mL	4.0950 mL	10.2375 mL
	15 mM	0.2730 mL	1.3650 mL	2.7300 mL	6.8250 mL
	20 mM	0.2048 mL	1.0238 mL	2.0475 mL	5.1188 mL
	25 mM	0.1638 mL	0.8190 mL	1.6380 mL	4.0950 mL
	30 mM	0.1365 mL	0.6825 mL	1.3650 mL	3.4125 mL
	40 mM	0.1024 mL	0.5119 mL	1.0238 mL	2.5594 mL
	50 mM	0.0819 mL	0.4095 mL	0.8190 mL	2.0475 mL
	60 mM	0.0683 mL	0.3413 mL	0.6825 mL	1.7063 mL
	80 mM	0.0512 mL	0.2559 mL	0.5119 mL	1.2797 mL
	100 mM	0.0410 mL	0.2048 mL	0.4095 mL	1.0238 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Uridine

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Mouse Metabolite Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Nucleotide Metabolite Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Uridine

All Endogenous Metabolite Isoforms